Prevention — Genetic Engineering, Screening and Emerging Technologies
When errors in DNA sequence or chromosome number cause non-infectious disease — from conception onwards. This lesson covers chromosomal and single-gene disorders, inheritance patterns, genetic screening and diagnosis, and the emerging frontier of gene therapy and CRISPR.
Practise this lesson
Four printable worksheets that build from the foundations up to exam-style questions — start at whatever level suits you.
Consider this claim: "CRISPR-Cas9 can now cure any genetic disease — if we can read the genome, we can fix it."
Write down what you know about genetic disorders and gene-editing technologies. Do you think this claim is accurate or an oversimplification? What would need to be true for it to be correct?
Know
- Types of genetic disorders: chromosomal abnormalities and single-gene (Mendelian) disorders
- Examples: Down syndrome, Turner, Klinefelter, CF, PKU, Huntington's, haemophilia
- Diagnostic tools: karyotyping, NIPT, amniocentesis, newborn screening
Understand
- How non-disjunction produces chromosomal abnormalities
- How mutations affect protein function and cause single-gene disorders
- How inheritance patterns (AR, AD, X-linked) predict disease risk
- The difference between screening and diagnostic tests
Can Do
- Classify a genetic disorder by type and inheritance pattern
- Evaluate the benefits, limitations and ethics of genetic diagnosis
- Assess gene therapy and CRISPR as prevention strategies
Core Content
Classification, causes and population burden
A genetic disorder arises from a heritable error in the DNA — either in the number or arrangement of entire chromosomes, or within the sequence of a single gene. Unlike environmental or nutritional diseases, the cause is written into the genome from the earliest stages of development.
Genetic disorders are classified into three main categories:
- Chromosomal disorders — abnormal chromosome number (aneuploidy) or structure (translocation, deletion, duplication). Examples: Down syndrome, Turner syndrome, Klinefelter syndrome.
- Single-gene (Mendelian) disorders — mutation in one gene disrupts normal protein function; follow predictable inheritance patterns. Examples: cystic fibrosis, Huntington's disease, haemophilia A.
- Multifactorial (polygenic and environmental) disorders — result from the interaction of multiple gene variants with environmental factors. Examples: Type 2 diabetes, heart disease, schizophrenia. These are harder to predict and do not follow simple Mendelian ratios.
This lesson focuses on chromosomal and single-gene disorders, as these have the clearest cause-and-effect pathways and the most direct diagnostic implications.
Inherited vs De Novo Mutations
Not all genetic disorders are inherited from a parent. De novo mutations arise spontaneously during gamete formation or early embryonic development and are not present in either parent. The majority of chromosomal abnormalities are de novo (caused by non-disjunction). Many single-gene disorders can be either inherited or de novo.
What to write in your book
- 3 categories: chromosomal (number/structure), single-gene (Mendelian), multifactorial (polygenic + environment).
- Chromosomal: Down, Turner, Klinefelter; single-gene: CF, Huntington's, haemophilia.
- De novo mutation = spontaneous, not in either parent (most chromosomal abnormalities are de novo).
- ~1 in 25 Australians affected by a rare genetic condition collectively.
Which set correctly lists the three main categories of genetic disorder?
Non-disjunction, trisomy, monosomy and translocation
Chromosomal abnormalities arise when gametes carry the wrong chromosome number — most often because homologous chromosomes fail to separate during meiosis. The fertilised egg then begins life with cells containing too many or too few chromosomes.
Non-Disjunction: The Core Mechanism
During meiosis I or meiosis II, chromosomes normally separate equally into daughter cells. Non-disjunction occurs when chromosomes fail to separate, producing one gamete with two copies of a chromosome and another with none.
Major Chromosomal Disorders
| Condition | Chromosome change | Karyotype | Key features | Frequency |
|---|---|---|---|---|
| Down syndrome | Trisomy 21 (extra chromosome 21) | 47, +21 | Intellectual disability (variable), characteristic facial features, heart defects, increased Alzheimer risk in adulthood | ~1 in 700 live births; rises steeply with maternal age |
| Edwards syndrome | Trisomy 18 | 47, +18 | Severe intellectual disability, heart/kidney malformations; most pregnancies end in miscarriage; median survival months | ~1 in 5,000 live births |
| Turner syndrome | Monosomy X (one X, no second sex chromosome) | 45, X0 (females only) | Short stature, infertility (streak ovaries), heart defects; normal intelligence; treated with oestrogen replacement | ~1 in 2,000 females |
| Klinefelter syndrome | Trisomy — extra X in males | 47, XXY (males only) | Taller stature, infertility (small testes, low testosterone), mild learning difficulties; often undiagnosed until adulthood | ~1 in 650 males |
Structural Chromosomal Abnormalities
Chromosomal disorders can also arise from structural rearrangements rather than number changes:
- Translocation — a segment of one chromosome breaks off and attaches to another. In familial Down syndrome, part of chromosome 21 is translocated onto chromosome 14; the individual has 46 chromosomes but 3 functional copies of chromosome 21. This can be inherited from a carrier parent.
- Deletion — loss of a chromosome segment (e.g. Cri-du-chat syndrome: deletion of part of chromosome 5).
- Duplication — a segment is copied twice, leading to overexpression of genes in that region.
The three major chromosomal disorders caused by nondisjunction, with karyotype notation, key features and population frequency.
What to write in your book
- Non-disjunction: chromosomes fail to separate in meiosis → gamete with two copies (n+1) and one with none (n−1).
- Trisomy 21 (Down, 47,+21); Turner (45,X0, female); Klinefelter (47,XXY, male).
- Structural: translocation (familial Down), deletion (Cri-du-chat), duplication.
- Maternal age ↑ trisomy 21 risk (oocytes arrested in meiosis I for decades).
The failure of chromosomes to separate during meiosis, producing gametes with an extra or missing chromosome, is called _____ (one word).
How one faulty gene can cause disease — and how it is passed on
Single-gene disorders follow the inheritance rules established by Mendel. The pattern of transmission — who is affected, which generations, which sexes — depends entirely on whether the allele is dominant or recessive, and whether it is carried on an autosome or a sex chromosome.
Autosomal Recessive (AR)
Both copies of the gene must be defective. Parents are often unaffected carriers (Aa). Each pregnancy of two carriers: 25% affected.
- Cystic Fibrosis (CFTR gene)
- PKU (PAH gene)
- Tay-Sachs (HEXA gene)
- Sickle-cell disease (HBB gene)
Autosomal Dominant (AD)
One faulty copy is sufficient. Affected individuals usually have one affected parent. Each pregnancy: 50% affected.
- Huntington's disease (HTT gene)
- Marfan syndrome (FBN1 gene)
- Neurofibromatosis type 1
- Familial hypercholesterolaemia
X-linked Recessive (XLR)
Gene is on X chromosome. Females with one copy are carriers (unaffected). Males with one copy are affected (only one X).
- Haemophilia A (F8 gene)
- Duchenne muscular dystrophy (DMD gene)
- Colour blindness (OPN1LW/OPN1MW genes)
Mitochondrial
Mutations in mitochondrial DNA. Inherited exclusively from the mother (mitochondria in egg, not sperm). All children of an affected mother are at risk.
- Leber hereditary optic neuropathy
- MELAS syndrome
Mechanism: Cystic Fibrosis (CF)
CF is caused by mutations in the CFTR gene on chromosome 7. CFTR encodes a chloride channel protein in the epithelial cell membrane. The most common mutation, delta-F508, causes the CFTR protein to misfold and be destroyed before reaching the cell surface.
Without functional CFTR, chloride ions cannot exit cells. Water follows chloride by osmosis — without water movement, mucus in the lungs, pancreatic ducts, and reproductive tract becomes abnormally thick. Consequences include chronic lung infections, pancreatic enzyme deficiency (malabsorption), and infertility in males.
Mechanism: Huntington's Disease (HD)
HD is caused by an expanded CAG trinucleotide repeat in the HTT gene on chromosome 4. Normal individuals have up to 35 CAG repeats; individuals with HD have 36 or more. The extra-long polyglutamine tract in the huntingtin protein causes it to misfold and aggregate in neurons, particularly in the striatum of the basal ganglia.
HD is autosomal dominant with virtually 100% penetrance — every individual who inherits the expanded allele will develop the disease if they live long enough (onset typically 30–50 years). HD shows anticipation: the repeat region tends to expand further in successive generations, causing earlier onset and more severe disease in children of affected individuals.
The genetic testing timeline from preconception carrier screening through newborn screening, plus the critical distinction between screening and diagnostic tests.
What to write in your book
- AR (CF, PKU): both copies mutated, parents carriers, 25% affected. AD (Huntington's): one copy enough, 50% affected.
- XLR (haemophilia A, DMD): gene on X; males affected, females carriers. Mitochondrial: maternal inheritance only.
- CF: CFTR (chr 7), ΔF508 misfolds → no Cl⁻ channel → thick mucus.
- HD: HTT CAG repeat (≥36) → toxic polyQ; autosomal dominant, 100% penetrance, anticipation.
Huntington's disease is autosomal dominant with ~100% penetrance and shows "anticipation". Anticipation means:
Karyotyping, NIPT, amniocentesis and newborn screening programs
Identifying genetic disorders early — before symptoms appear, during pregnancy, or at birth — gives patients, families and clinicians the ability to make informed decisions about management. It is critical to distinguish between screening (risk assessment of a population) and diagnosis (definitive confirmation in an individual).
| Test | Type | How it works | Timing | Risk / Limitations |
|---|---|---|---|---|
| Karyotyping | Diagnostic | Cells cultured, chromosomes stained and photographed at metaphase; arranged by size and banding pattern to detect aneuploidy or structural changes | Postnatal (blood), or prenatal after invasive sampling | Cannot detect single-gene mutations; limited resolution for small deletions |
| NIPT | Screening | Analyses cell-free fetal DNA (cfDNA) shed into maternal blood; detects over- or under-representation of chromosomal DNA sequences | From 10 weeks gestation | Screening only — positive result requires diagnostic confirmation; twin pregnancies complicate interpretation; does not detect all abnormalities |
| Amniocentesis | Diagnostic | Needle inserted through abdomen into amniotic fluid (15–20 weeks); fetal cells grown and karyotyped or tested for specific gene mutations by PCR/DNA sequencing | 15–20 weeks gestation | ~0.5% miscarriage risk; cannot be done early; results take 2–4 weeks (culture) or days (FISH) |
| CVS (chorionic villus sampling) | Diagnostic | Small amount of placental tissue taken 10–13 weeks; earlier result than amniocentesis | 10–13 weeks gestation | ~1% miscarriage risk; cannot detect neural tube defects; slightly higher risk than amniocentesis |
| Newborn screening (Guthrie card) | Screening | Dried blood spot collected from heel at 48–72 hours; screened for metabolic and endocrine disorders (PKU, congenital hypothyroidism, galactosaemia, CF) | 48–72 hours after birth | Universal in Australia; false positives possible; does not detect chromosomal disorders |
| Carrier testing | Diagnostic | DNA test for adults with family history of AR or XLR conditions; identifies heterozygous carriers of CF, fragile X, spinal muscular atrophy | Any time — ideally before pregnancy | Does not confirm disease; psychological impact; may affect insurance eligibility |
Green rows = lower procedural risk. Red-tinted rows = invasive procedures with miscarriage risk.
Preimplantation Genetic Testing (PGT)
For couples at high risk of passing on a serious genetic disorder (e.g. both carriers of CF), IVF can be combined with preimplantation genetic testing. One or two cells are removed from a day-5 blastocyst and tested by PCR or chromosomal microarray. Only unaffected embryos are transferred to the uterus. PGT avoids the ethical difficulty of terminating an established pregnancy, but IVF is invasive, costly, and not always successful.
What to write in your book
- Screening (NIPT, newborn Guthrie) = risk assessment, broad, false positives; Diagnostic (karyotype, amnio, CVS) = definitive but higher risk.
- NIPT: cfDNA in maternal blood, 10 wk+, no miscarriage risk, screening only.
- Amniocentesis (15–20 wk, ~0.5% miscarriage) and CVS (10–13 wk, ~1%) = diagnostic.
- PGT: test IVF embryos, transfer only unaffected ones; avoids termination but needs IVF.
NIPT (non-invasive prenatal testing) is a diagnostic test that definitively confirms a chromosomal disorder.
Genetic screening can identify individuals at risk of inherited disorders before symptoms develop, enabling early intervention.
Genetic screening can predict all future diseases with 100% accuracy, including those caused solely by environmental factors.
Gene therapy, CRISPR and the limits of genetic intervention
Most genetic disorders cannot currently be cured — management aims to treat symptoms and compensate for defective protein function. Gene therapy offers the prospect of addressing the root cause, but its clinical application remains limited and raises significant ethical questions.
Current Management Strategies
- Symptomatic treatment — physiotherapy and DNase inhalation for CF lung disease; insulin for Type 1 diabetes; clotting factor infusions for haemophilia
- Dietary modification — phenylalanine-restricted diet for PKU prevents neurological damage; galactose-free diet for galactosaemia
- CFTR modulators (targeted therapy) — drugs such as ivacaftor, tezacaftor and elexacaftor directly improve CFTR protein function in patients with specific mutations (e.g. delta-F508 homozygotes). A major advance, but not applicable to all CF mutations.
- Hormone replacement — oestrogen for Turner syndrome; growth hormone for short stature disorders
Gene Therapy
Gene therapy delivers a functional copy of a defective gene into patient cells. The two main delivery systems are:
- Viral vectors — modified adeno-associated viruses (AAV) or lentiviruses carry the therapeutic gene into cells. Approved therapies include Luxturna (RPE65 mutation causing blindness) and Zolgensma (spinal muscular atrophy).
- CRISPR-Cas9 — molecular scissors that can cut DNA at a precise location guided by a short RNA sequence, then either disrupt a gene or template-guide repair to correct a mutation. Approved in 2023 for sickle-cell disease and beta-thalassaemia (Casgevy — the first CRISPR therapy approved globally).
Ethical Considerations in Genetic Medicine
Genetic medicine raises ethical questions that go beyond the science: access equity (life-changing therapies such as Casgevy cost ~AUD $3.5 million per patient — who can access them?); genetic discrimination (carrier or predictive test results may affect insurance or employment); reproductive autonomy (who decides which embryos are selected in PGT, and on what grounds?); and the germline editing debate (heritable edits to future generations are banned in most countries because of unknown long-term and off-target effects). Balancing the prevention of suffering against the dignity of those living with genetic conditions is central to IQ4.
What to write in your book
- Most genetic disorders managed (symptomatic, dietary, CFTR modulators, hormone replacement), not cured.
- Gene therapy: viral vectors deliver functional gene (Luxturna, Zolgensma); CRISPR-Cas9 cuts/corrects DNA.
- Casgevy (2023) = first approved CRISPR therapy (sickle-cell, β-thalassaemia).
- Somatic editing (individual only) vs germline (heritable, banned); ethics: access equity, discrimination, autonomy.
CRISPR-Cas9 gene therapy can currently cure any genetic disease.
CRISPR gene editing could potentially prevent genetic diseases by correcting disease-causing mutations in embryos.
Population-wide genetic screening has no ethical implications because genetic information is completely private and cannot be misused.
In November 2023, the US FDA approved Casgevy (exa-cel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, for sickle-cell disease and beta-thalassaemia. It works by reactivating fetal haemoglobin production in the patient's own stem cells using CRISPR-Cas9 — effectively providing a functional replacement for defective adult haemoglobin.
Cost: approximately AUD $3.5 million per patient for a single treatment. This raises the fundamental question explored in IQ4: even when prevention or cure is technically possible, how do societies decide who can access it?
Chromosomal Disorders
- Cause: non-disjunction during meiosis
- Trisomy 21 (Down): 47,+21; intellectual disability, heart defects
- Turner (45,X0): monosomy X; female, infertile, short stature
- Klinefelter (47,XXY): extra X in males; infertile, tall
- Translocation: 46 chromosomes but 3 copies of chr 21 function — familial Down
Single-Gene Disorders
- AR: CF (CFTR), PKU (PAH) — both copies mutated, parents carriers
- AD: Huntington's (HTT, CAG repeat), Marfan — one copy sufficient
- XLR: Haemophilia A (F8), DMD — males affected, females carriers
- HD: 100% penetrance, anticipation (repeat expands each generation)
Genetic Diagnosis
- Karyotype: chromosome number/structure; not single genes
- NIPT: cfDNA in maternal blood; screen only (10 weeks+)
- Amniocentesis: amniotic fluid; diagnostic; 0.5% miscarriage risk (15–20 wk)
- CVS: placental tissue; earlier (10–13 wk); 1% miscarriage risk
- Newborn screening (Guthrie card): PKU, CF, hypothyroidism at 48 h
Prevention and Ethics
- Gene therapy: viral vectors deliver functional gene (Luxturna, Zolgensma)
- CRISPR: approved 2023 for sickle-cell/thalassaemia (Casgevy)
- Somatic editing: individual only; germline: heritable (banned most countries)
- Ethics: access equity, genetic discrimination, reproductive autonomy, off-target effects
Inheritance Pattern Detective
For each genetic disorder below, classify its inheritance pattern and complete the fields. Then answer the questions that follow.
Cystic fibrosis
Huntington's disease
Haemophilia A
Down syndrome (trisomy 21)
PKU
A — Pedigree interpretation: In a family, a mother is an unaffected carrier of haemophilia A and the father is unaffected. What are the probabilities that (i) a son is affected; (ii) a daughter is a carrier? Show your working using a Punnett square.
B — Risk calculation: Both of Priya's parents are carriers of cystic fibrosis but are unaffected themselves. Priya is unaffected. What is the probability that Priya is a carrier? (Hint: consider all possible unaffected genotypes.)
Evaluating Gene Therapy as a Prevention Strategy
- Explain why DMD predominantly affects males. Include a description of the inheritance pattern.
- Describe two benefits and two limitations of using CRISPR-Cas9 to treat DMD. Use specific biological evidence.
- A family asks whether the CRISPR therapy could be used during IVF to prevent their child from inheriting DMD entirely (germline editing). Evaluate the scientific and ethical implications of this approach compared to preimplantation genetic testing (PGT).
A fresh set drawn from this lesson's question bank — feedback shown immediately. +5 XP per correct · +25 XP all correct
Pick your answer, then rate your confidence — that tells the system what to drill next.
UnderstandBand 3–4(4 marks) 1. Explain how non-disjunction during meiosis can result in Turner syndrome. In your answer, describe the chromosome abnormality present and outline two clinical features of the condition.
AnalyseBand 5(5 marks) 2. Compare the usefulness of NIPT (non-invasive prenatal testing) and amniocentesis as methods of detecting chromosomal abnormalities during pregnancy. Refer to: the type of test (screening vs diagnostic), procedural risk, timing, and information provided.
EvaluateBand 6(6 marks) 3. Evaluate the statement: "Advances in genetic technology mean that genetic disorders will soon be entirely preventable." Discuss gene therapy (including CRISPR), preimplantation genetic testing, and genetic screening programs. Consider both the scientific and ethical dimensions.
Show all answers
Multiple choice
MC answers and full explanations are shown inline as you complete each question. Use the retry button to attempt a fresh set from the lesson bank.
Activity 1 — Inheritance Pattern Detective
Classifications: Cystic fibrosis — autosomal recessive (carrier unaffected; 25% risk from two carriers). Huntington's — autosomal dominant (one copy causes disease; no unaffected "carrier"; 50% risk from one affected parent). Haemophilia A — X-linked recessive (female carriers unaffected; affected males). Down syndrome — chromosomal (trisomy 21, usually de novo non-disjunction; not a simple carrier model). PKU — autosomal recessive (carrier unaffected; 25% risk from two carriers).
A — Haemophilia Punnett square: Mother XHXh (carrier) × Father XHY → offspring XHXH (normal daughter), XHXh (carrier daughter), XHY (normal son), XhY (affected son). (i) P(son affected) = 1/2 (50%). (ii) P(daughter carrier) = 1/2 (50%).
B — Carrier probability for Priya: Both parents Aa. Unaffected offspring: AA (1/4) and Aa (2/4). Of the 3/4 that are unaffected, 2/4 are carriers, so P(Priya is a carrier | unaffected) = 2/3 (~67%).
Activity 2 — Gene Therapy Evaluation (DMD)
1. DMD is X-linked recessive (DMD gene on the X chromosome). Males have only one X, so a single mutated copy causes disease (no second X to compensate). Females have two X chromosomes — a mutation on one is usually compensated by the normal allele on the other, so they are typically unaffected carriers. Hence DMD predominantly affects males. 2. Benefits: addresses the root cause by restoring functional dystrophin production (exon-skipping), potentially durable in edited stem cells. Limitations: delivering CRISPR machinery to enough muscle cells throughout the body is extremely difficult; off-target edits risk; somatic editing does not prevent inheritance; cost ~$3M and Phase 2 (not yet proven/approved). 3. Germline editing during IVF would be heritable (preventing DMD in all descendants) but is banned in most countries due to off-target risks and ethical concerns about modifying future generations who cannot consent. PGT, by contrast, selects unaffected IVF embryos without editing any DNA — it is currently available and ethically accepted, though it requires IVF and raises embryo-selection questions. Scientifically, PGT is established and lower-risk; germline editing is experimental and prohibited.
Short Answer Model Answers
SA1 (4 marks): Non-disjunction occurs when sex chromosomes fail to separate during meiosis I or II (usually in the mother), producing an egg with no X chromosome. Fertilised by an X-bearing sperm, this gives a 45,X0 zygote — Turner syndrome [1 mechanism + 1 karyotype]. Two clinical features (1 each, any two): short stature (SHOX haploinsufficiency); gonadal dysgenesis/infertility (streak ovaries, needs oestrogen for puberty); heart defects (coarctation of the aorta); webbed neck/lymphoedema.
SA2 (5 marks): NIPT — a screening test (identifies risk, doesn't diagnose); analyses cell-free fetal DNA in maternal blood; from 10 weeks; no procedural miscarriage risk; highly sensitive for trisomies 21/18/13 but a positive result needs confirmation; doesn't detect most single-gene/structural abnormalities [2]. Amniocentesis — a diagnostic test (definitive); fetal cells from amniotic fluid karyotyped or sequenced; at 15–20 weeks; ~0.5% miscarriage risk; detects chromosomal AND single-gene disorders; results in days–weeks [2]. Comparison: NIPT is used first (low-risk, early) to flag at-risk pregnancies; amniocentesis confirms a positive NIPT or is offered for older maternal age/family history — a trade-off between risk, certainty and timing [1].
SA3 (6 marks): Judgement: the statement is an oversimplification — genetic disorders will not be "entirely" preventable in the near future. Gene therapy/CRISPR (2 marks): Casgevy (2023, sickle-cell/β-thalassaemia) is a genuine breakthrough, but somatic editing does not prevent inheritance, germline editing is banned, delivery to many organs remains unsolved, and ~$3M cost limits access — so CRISPR is not a population-level prevention strategy. PGT and prenatal screening (2 marks): PGT selects unaffected IVF embryos (effective for known single-gene risk but needs IVF); NIPT/amniocentesis enable prenatal detection, but prevention then depends on termination decisions; access is inequitable globally. Scientific/ethical evaluation (2 marks): de novo chromosomal disorders cannot be prevented by gene therapy (require diagnosis/embryo selection); multifactorial disorders — most of the disease burden — are not addressable by single-gene approaches; ethical issues include reproductive autonomy, genetic discrimination, eugenics risk, and equity. Balanced conclusion: prevention is increasingly possible for specific single-gene disorders, but "entirely preventable" ignores multifactorial complexity, equity barriers and ethical limits.
Five timed questions on chromosomal and single-gene disorders, inheritance patterns, screening and gene therapy. Beat the boss to bank a tier — gold (perfect + fast), silver (80%+), or bronze (cleared).
⚔ Enter the arenaUse all your knowledge of genetic disorders, inheritance, screening and CRISPR to defeat the boss. Pool: lessons 1–17.
At the start you evaluated the claim that "CRISPR-Cas9 can now cure any genetic disease." Return to what you wrote and consider:
- CRISPR was approved for its first clinical use (sickle-cell disease) in 2023 — but only for one disorder affecting accessible blood cells. Applying it to other organs, chromosomal disorders, or multifactorial diseases faces entirely different challenges.
- The claim is an oversimplification. Gene therapy is advancing rapidly, but delivery, off-target effects, cost, and the somatic vs germline distinction all limit its current scope.
- Prevention also involves screening programs (newborn, prenatal, carrier testing) and PGT — more widely available now than gene therapy.